LivaNova PLC (NASDAQ:LIVN) Given Average Rating of “Moderate Buy” by Brokerages

LivaNova PLC (NASDAQ:LIVN) has received an average recommendation of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $61.17.

LIVN has been the subject of a number of recent analyst reports. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of LivaNova in a research report on Monday. Barclays dropped their price target on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research report on Friday, March 7th. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Finally, Mizuho lowered their price objective on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its stake in LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in LivaNova by 1.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after acquiring an additional 289 shares during the last quarter. Atria Investments Inc lifted its stake in LivaNova by 6.2% in the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after acquiring an additional 331 shares during the last quarter. Xponance Inc. lifted its stake in LivaNova by 6.1% in the fourth quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after acquiring an additional 445 shares during the last quarter. Finally, Mariner LLC lifted its stake in LivaNova by 8.4% in the fourth quarter. Mariner LLC now owns 5,741 shares of the company’s stock worth $266,000 after acquiring an additional 446 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of LIVN opened at $40.84 on Thursday. LivaNova has a 1-year low of $36.85 and a 1-year high of $64.48. The stock has a market cap of $2.22 billion, a PE ratio of 97.24 and a beta of 1.10. The firm has a 50-day simple moving average of $45.60 and a two-hundred day simple moving average of $48.89. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.